We have been using DEX for refractory DME for a long time (since 2016). Thus, we are sharing our results , evaluating both anatomical and functional outcomes of DEX therapy for refractory DME.
Our study aims at evaluating both anatomical and functional outcomes of DEX therapy for cases of refractory DME, with both a single injection, and /or with retreatments.
Study Type
OBSERVATIONAL
Enrollment
58
Intravitreal Dexamethasone implants (DEX) (0.7 mg) (Ozurdex, Allergan, Inc, Irvine, CA, USA) had been used with greater efficacy and safety in DME.
Kasr alainy faculty of medicine
Cairo, Egypt
Change in Central macular thickness (in microns) (CMT change )
Change in Central macular thickness (in microns) (CMT change )
Time frame: between baseline and 6 months
Change in Best corrected visual acuity (BCVA change) )
lines of Change in Best corrected visual acuity (BCVA change) )
Time frame: between baseline and 6 months
Number of DEX injections
Number of DEX injections
Time frame: between baseline and 6 months
Shift to anti-VEGF during follow-up
Shift to anti-VEGF during follow-up (Yes or No)
Time frame: between baseline and 6 months
Duration of follow-up ( months)
Duration of follow-up ( months)
Time frame: between baseline and 6 months
CMT change > 100 u
CMT change \> 100 u (yes / No)
Time frame: between baseline and 6 months
CMT change > 200 u
CMT change \> 200 u (yes / No)
Time frame: between baseline and 6 months
BCVA change >= 2 lines
BCVA change \>= 2 lines (yes / No)
Time frame: between baseline and 6 months
Complications : ocular hypertension, pseudo uveitis, endophthalmitis, RD
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Complications : ocular hypertension, pseudo uveitis, endophthalmitis, RD (yes / No)
Time frame: between baseline and 6 months